Flesinoxan

Flesinoxan

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 4-fluoro-N-(2-{4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide
CAS Number	98206-10-1
PubChem CID	57347
IUPHAR/BPS	1
ChemSpider	51700
UNII	3V574S89E1
KEGG	D02568
ChEMBL	CHEMBL1742477
Chemical and physical data
Formula	C22H26FN3O4
Molar mass	415.458 g/mol
3D model (Jmol)	Interactive image
SMILES C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO
InChI InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1 Key:NYSDRDDQELAVKP-SFHVURJKSA-N

Flesinoxan (DU-29,373) is a potent and selective 5-HT_1A receptor partial/near-full agonist of the phenylpiperazine class. Originally developed as a potential antihypertensive drug, flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests. As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability. Unfortunately however, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.

In patients, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion.